<DOC>
	<DOC>NCT02241941</DOC>
	<brief_summary>The purpose of this study is to determine single dose pharmacokinetics of daptomycin consecutively in 10 patients on three different time points after severe burn injury.</brief_summary>
	<brief_title>Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Burns</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Male or female of 18 years or older Second and/or third degree thermal injury Total body surface area burned ≥ 15% Hospitalisation in the ICU for burn injured patients of the University Hospital Zürich Probability of ICU stay of &gt;14 days Written informed consent by the patient or in patients unable to be informed or to sign according to section 4.4 of the study protocol Evidence of renal failure (Creatinine clearance &lt;30ml/min) or continuous renal replacement therapy such as continuous hemofiltration History of muscle disease or skeletal muscle disorder Creatinephosphokinase (CPK) ≥ 5 times the upper limit of normal (ULN) History of hypersensitivity to the drug Pregnancy Severe coagulation disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>